Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
ID: 356978Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356978

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-103.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-103-Full-Announcement.html
    PAR-25-103.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), announces a funding opportunity titled the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34). This program aims to facilitate the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. It seeks to address information gaps, such as population characteristics and operational risks, that hinder effective trial protocols. Applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research teams and participant recruitment, as diverse perspectives improve research outcomes. Key dates include a submission deadline of January 25, 2025, with funding of up to $225,000 per year available for planning initiatives. Eligible organizations range from higher education institutions to non-profits and tribal governments. The U34 grants will support preparatory research to solidify future trials' feasibility, emphasizing rigorous design and a comprehensive understanding of the study population and intervention methods. Applications must outline detailed planning activities, address barriers to implementation, and include assessment strategies for diversity and inclusion, with a maximum project period of three years. This opportunity reinforces NCI's commitment to improving cancer care through well-designed research initiatives.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for R34 Clinical Trial Pilot Studies aimed at supporting research that informs the planning of Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders. Applicants are required to demonstrate that their proposed studies are essential for the design of future trials and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote diversity within research teams. This initiative is critical for advancing clinical practice and understanding in these vital health areas, with awards of up to $450,000 available over three years. Interested applicants should submit their proposals by January 7, 2027, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial Not Allowed) to support federally recognized American Indian/Alaska Native Tribes and Tribal entities in preparing competitive NARCH applications. The primary objective of this grant program is to enhance research capacity and train future scientists by enabling eligible organizations to conduct preparatory work for future applications, with a maximum budget of $225,000 in annual direct costs for a two-year project. Eligible applicants may submit one application per due date, and must not currently hold a NARCH S06 award or an active NARCH Planning Grant. The application process requires a detailed plan outlining goals, administrative capacity, allowable components, and potential collaborators, with a deadline for submission set for July 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-441.html.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.